An Intergroup Randomised Trial of Rituximab Versus a Watch and Wait Strategy in Patients With Advanced Stage, Asymptomatic, Non-Bulky Follicular Lymphoma.
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 31 Oct 2017
At a glance
- Drugs Rituximab (Primary)
- Indications Follicular lymphoma
- Focus Registrational; Therapeutic Use
- 14 Nov 2016 Planned End Date changed from 1 Oct 2011 to 1 May 2022.
- 06 Dec 2010 Preliminary results will be reported at ASH 2010.
- 06 Dec 2010 According to a Roche media release, full study results will be presented in an abstract at the 52nd American Society of Hematology (ASH).